Socioeconomic consequences of the COVID-19 pandemic for people who use drugs
S. Walker, P. Dietze, P. Higgs, B. Ward, C. Treloar, M. Stoové, K. Rathnayake, J. Doyle, M. Hellard, L. Maher
COVID-19 disaster recovery capitals: A conceptual framework to guide holistic and strengths-based support strategies
Quinn P, Munari S, Block K, Walker S, Liberman J, Wallace J, Horyniak D, Oliver J, Hellard M, Fletcher-Lartey S, Gibbs L
COVID-19
Evaluation of an Online Training Program on COVID-19 for Health Workers in Papua New Guinea
Mohamed Y, Hezeri P, Kama H, Mills K, Walker S, Hau'ofa N, Amol C, Jones M, du Cros P, Lin YD
COVID-19
Police custody in Australia: A call for transparency and accountability.
Walker S, Wilson M, Seear K, Doyle M, Saich F, Stoové M, Winter R
Justice Health
Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study.
Curtis M, Wilkinson AL, Dietze P, Stewart AC, Kinner SA, Winter RJ, Aitken C, Walker SJ, Cossar RD, Butler T, Stoové M
Prospective study of retention in opioid agonist treatment and contact with emergency healthcare following release from prisons in Victoria, Australia.
Curtis M, Wilkinson AL, Dietze P, Stewart AC, Kinner SA, Cossar RD, Nehme E, Aitken C, Walker S, Butler T, Winter RJ, Smith K, Stoove M